secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMPACT BIOMEDICAL INC. (IBO)
CIK:        0001834105
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001641172-25-016002
Event type: m_and_a
Sentiment:  negative
Materiality: 1.00
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Impact BioMedical announces reverse merger with Dr Ashleys; shareholders to receive 4.80% of combined entity
--------------------------------------------------------------------------------

- Impact BioMedical (IBO) will merge with Dr Ashleys via a reverse merger; existing Impact shareholders receive 4.80% of the new PubCo's ordinary shares.
- Dr Ashleys shareholders get 94.20% of PubCo; Dr Ashleys management will control the combined company's board and operations.
- 86.81% of Impact's shareholders (by as-converted shares) have signed a voting agreement to approve the deal.
- Closing conditions include Impact having at least $10,000 net cash and zero net debt, and NYSE American listing approval.
- The combined entity will be renamed Dr Ashleys Limited and continue trading on NYSE American under a new name.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/0001641172-25-016002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834105/000164117225016002/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-016002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer